Keywords: schwarz, leads, french, migraine, market, pharma, germany

Schwarz Leads French Migraine Market

Article | 18 August 1998

Schwarz Pharma of Germany, which acquired the worldwide rights to theantimigraine drug Seglor (dihydroergotamine mesylate) from France's Sanofi in July ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Companies

Schwarz Pharma

Go to company listing

Related Drugs

D. H. E. 45

Dihydroergotamine

Go to drug listing